TY - CONF
T1 - Review of patients with necrotising enterocolitis treated in Children’s Clinical University Hospital Riga from 2015 to 2020
AU - Karlsons, Jānis
AU - Ozoliņa, Sandra
AU - Snipe, Hilda
AU - Ābola, Zane
PY - 2021/3/24
Y1 - 2021/3/24
N2 - Necrotising enterocolitis (NEC) is a devastating bowel disease affecting 3-10% of very preterm infants. It is associated with increased mortality, serious neonatal morbidity and decreased quality of life in survivors. Aim was to compare and analyze patient data with NEC regarding demographics, therapeutics, time of diagnosis and proportion of surgical treatment from 2015 to 2020 and compare data with literature. 2455 patient history charts with diagnosis of SSK 10 classifier P77 and P07 was overlooked from 2015 to 2020 to find patient with NEK diagnosis using data storage system Andromeda in Children’s Clinical University Hospital (CCUH). Statistical analysis were performed in MS Excel and IBM SPSS. From 2015-2020 110 patients with NEC where treated in CCUH. Incidence 4,5%. 52 (47,3%) female and 58 (52,7%) male. According to gestational age: extremely preterm 55(50%), very preterm 44 (40%), late preterm 9 (8,2%), term 2(1,8%). According to birth weight: < 1000g 54(49,1%), 1000-1499g 37(33,6%), 1500-2499g 16 (14,5%), 2500-3999g 3(2,7%). In 57 (52%) NEC presented in a first week of life, in 48 (44%) patient >7 days, mean 16 days.
From 110 patient with NEK 20 (18,2%) required surgery. From those 1(5%) received breast milk, 12 (60%) formula, 5(25%) combined, in conservative group 33(36,7%) breast milk, 28 (31%) formula and 21 (23%) combined. 5(25%) of surgically treated presented at first 7 days of life. 19 (85%) patient in surgical group was less than 1499g and <32 weeks of gestation.
The most commonly used antibacterial combination is ampicillin/gentamicin (n=32; 29,1%), in surgical group piperacillin/tazobactam/vancomycin (n=5; 25%). To improve statistics more careful marking of diagnosis in Andromeda is required.The lower the weight and gestational age, the greater the chance of developing advanced NEC and requirement for surgical treatment.In statistical analyses demographics, therapeutics and time of diagnosis corresponds to data found in literature.
AB - Necrotising enterocolitis (NEC) is a devastating bowel disease affecting 3-10% of very preterm infants. It is associated with increased mortality, serious neonatal morbidity and decreased quality of life in survivors. Aim was to compare and analyze patient data with NEC regarding demographics, therapeutics, time of diagnosis and proportion of surgical treatment from 2015 to 2020 and compare data with literature. 2455 patient history charts with diagnosis of SSK 10 classifier P77 and P07 was overlooked from 2015 to 2020 to find patient with NEK diagnosis using data storage system Andromeda in Children’s Clinical University Hospital (CCUH). Statistical analysis were performed in MS Excel and IBM SPSS. From 2015-2020 110 patients with NEC where treated in CCUH. Incidence 4,5%. 52 (47,3%) female and 58 (52,7%) male. According to gestational age: extremely preterm 55(50%), very preterm 44 (40%), late preterm 9 (8,2%), term 2(1,8%). According to birth weight: < 1000g 54(49,1%), 1000-1499g 37(33,6%), 1500-2499g 16 (14,5%), 2500-3999g 3(2,7%). In 57 (52%) NEC presented in a first week of life, in 48 (44%) patient >7 days, mean 16 days.
From 110 patient with NEK 20 (18,2%) required surgery. From those 1(5%) received breast milk, 12 (60%) formula, 5(25%) combined, in conservative group 33(36,7%) breast milk, 28 (31%) formula and 21 (23%) combined. 5(25%) of surgically treated presented at first 7 days of life. 19 (85%) patient in surgical group was less than 1499g and <32 weeks of gestation.
The most commonly used antibacterial combination is ampicillin/gentamicin (n=32; 29,1%), in surgical group piperacillin/tazobactam/vancomycin (n=5; 25%). To improve statistics more careful marking of diagnosis in Andromeda is required.The lower the weight and gestational age, the greater the chance of developing advanced NEC and requirement for surgical treatment.In statistical analyses demographics, therapeutics and time of diagnosis corresponds to data found in literature.
M3 - Abstract
SP - 75
T2 - RSU Research week 2021: Knowledge for Use in Practice
Y2 - 24 March 2021 through 26 March 2021
ER -